Goldman Sachs logo
Goldman Sachs

May 14, 2026

Sysmex Earnings Review Results In Line

Single Stock ReportEquitiesHealth Care

Sysmex's FY3/26 results met expectations on an underlying basis, but FY3/27 guidance missed consensus due to risks in China and inflation. Goldman Sachs maintains a Buy rating with a reduced target price of ¥1,700.

Key Takeaways

  • 1.FY3/26 results were broadly in line with expectations, excluding a one-time impairment loss.
  • 2.FY3/27 operating profit guidance is below consensus due to price pressure in China and rising SG&A costs.
  • 3.Goldman Sachs maintains a Buy rating but has lowered the 12-month target price to ¥1,700.

Table of Contents

  • Earnings overview and GSe revisions
  • GS Forecast
  • GS Factor Profile
  • Ratios & Valuation
  • Growth & Margins (%)
  • Price Performance
  • Income Statement (¥ bn)
  • Balance Sheet (¥ bn)
  • Cash Flow (¥ bn)
  • Price Target Risks and Methodology - Sysmex
  • Investment Thesis - Sysmex
  • Disclosure Appendix

Document Preview

Page 1 of 5
Page 1 of Sysmex Earnings Review Results In Line
Subscribe for full access

Access the Full Report

Get unlimited access to institutional research reports with a 14-day free trial.

Authors

Akinori Ueda, Ph.D.Tomo Taniguchi

Securities

Sysmex

Themes

China Market DeteriorationInflationary Cost PressuresMedical Diagnostics Innovation

Regions

Asia PacificEuropeNorth AmericaJapanChinaUnited States